Stock Events

Stock Events

Alector 

$2.46
43
+$0.10+4.24% Wednesday 20:00
+$0.03+1.22%Wednesday 23:55After hours

Statistics

Day High
2.46
Day Low
2.45
52W High
3.4
52W Low
1.09
Volume
31,219
Avg. Volume
-
Mkt Cap
274.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.62
-0.42
-0.22
-0.02
Expected EPS
-0.228571
Actual EPS
N/A

Financials

-679.16%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
21.05MRevenue
-142.93MNet Income

Analyst Ratings

6.00Average Price Target
The highest estimate is 6.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALEC. It's not an investment recommendation.
Tesla
7
TSLA
Bitcoin
7
BTC.CRYPTO
Apple
6
AAPL
Pfizer
6
PFE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.03B
Biogen focuses on neurodegenerative diseases, directly competing with Alector's Alzheimer's and dementia treatments.
Anavex Life Sciences
AVXL
Mkt Cap300.34M
Anavex Life Sciences works on treatments for Alzheimer's disease, directly competing with Alector's pipeline.
AC Immune SA
ACIU
Mkt Cap288.34M
AC Immune develops precision medicine for neurodegenerative diseases, including Alzheimer's, similar to Alector's focus.
Prothena
PRTA
Mkt Cap485.13M
Prothena Corporation focuses on therapies for neurodegenerative diseases, closely competing with Alector's portfolio.
Ionis Pharmaceuticals
IONS
Mkt Cap9.93B
Ionis Pharmaceuticals develops drugs for neurological disorders, competing in the same space as Alector.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.61B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, including neurodegenerative disorders, competing with Alector.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics is involved in gene editing for various diseases, including potential treatments for neurodegenerative diseases, indirectly competing with Alector.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, including a focus on genetic therapies that could address neurodegenerative diseases, indirectly competing with Alector.
Novartis
NVS
Mkt Cap301.95B
Novartis AG, a large pharmaceutical company, has a broad portfolio that includes treatments for neurodegenerative diseases, making it a competitor in the same therapeutic area as Alector.

About

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Show more...
CEO
Arnon Rosenthal
Employees
103
Country
United States
ISIN
US0144421072
WKN
000A2PCBM

Listings

MU
DE
0Z2.MU
STU
DE
0Z2.STU
XNAS
US
ALEC
F
DE
0Z2.F

0 Comments

Share your thoughts

FAQ

What is Alector stock price today?▼
The current price of ALEC is $2.46 USD — it has increased by +4.24% in the past 24 hours. Watch Alector stock price performance more closely on the chart.
What is Alector stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Alector stocks are traded under the ticker ALEC.
Is Alector stock price growing?▼
ALEC stock has risen by +8.85% compared to the previous week, the month change is a +62.91% rise, over the last year Alector has showed a +2.5% increase.
What is Alector market cap?▼
Today Alector has the market capitalization of 274.68M
When is the next Alector earnings date?▼
Alector is going to release the next earnings report on November 10, 2026.
What were Alector earnings last quarter?▼
ALEC earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.23 USD resulting in a +8.12% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Alector revenue for the last year?▼
Alector revenue for the last year amounts to 21.05M USD.
What is Alector net income for the last year?▼
ALEC net income for the last year is -142.93M USD.
How many employees does Alector have?▼
As of August 27, 2026, the company has 103 employees.
In which sector is Alector located?▼
Alector operates in the Health & Wellness sector.
When did Alector complete a stock split?▼
Alector has not had any recent stock splits.
Where is Alector headquartered?▼
Alector is headquartered in SOUTH SAN FRANCISCO, United States.